As of April 1, 2026, Executive Senior Managing Officer Eiji Sato will be appointed Director of Taiyo Pharma Co., Ltd., and Terumichi Tawara will be transferred to Director of the same company.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4626","jir_company_name":"Taiyo Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4626-20260204-04.pdf","jir_short_summary":"As of April 1, 2026, Executive Senior Managing Officer Eiji Sato will be appointed Director of Taiyo Pharma Co., Ltd., and Terumichi Tawara will be transferred to Director of the same company.","jir_summary":"### Overview of Personnel Changes\nTaiyo Holdings Co., Ltd. resolved at the Board of Directors meeting held on February 4, 2026, the personnel changes effective April 1, 2026. Executive Senior Managing Officer Eiji Sato will be appointed Director of Taiyo Pharma Co., Ltd., and concurrently serve as Director of Fanlead Co., Ltd. and Taiyo Pharmatech Co., Ltd. Meanwhile, Terumichi Tawara will continue as Executive Senior Managing Officer, Chief Digital Officer, and head of the Information Systems Department, while transferring to Director of Taiyo Pharma Co., Ltd.\n\n### Future Impact and Procedures\nAppointments and resignations will be conducted once necessary procedures at each subsidiary are completed. These personnel changes aim to strengthen the management structure and promote digital strategy, contributing to the company's sustainable growth. Investors will focus on the stability of business operations and the clarification of strategic directions resulting from this management refresh.","jir_financial_highlights":"Effective Date of Personnel Changes: 2026\u5e744\u67081\u65e5 (Unknown)\nNew Director: Eiji Sato (Unknown)\nDirector Transfer Destination: Taiyo Pharma Co., Ltd., Fanlead Co., Ltd., Taiyo Pharmatech Co., Ltd. (Unknown)","jir_category":"","jir_hashtags":"#TaiyoHoldings, #executive_change, #JapaneseStocks","jir_key_figures":"Effective Date: 2026\u5e744\u67081\u65e5\nNew Director: Eiji Sato\nDirector Transfer Destination: Taiyo Pharma Co., Ltd., Fanlead Co., Ltd., Taiyo Pharmatech Co., Ltd.","jir_meta_title":"Taiyo Holdings Co., Ltd. Announces Personnel Changes Effective April 1, 2026","jir_meta_description":"Taiyo Holdings Co., Ltd. announced personnel changes effective April 1, 2026, with Executive Senior Managing Officer Eiji Sato appointed as Director. These key executive changes aim to strengthen the management structure.","jir_og_title":"Taiyo Holdings Co., Ltd. Notice of Personnel Changes (Effective April 1, 2026)","jir_og_description":"Taiyo Holdings Co., Ltd. resolved executive personnel changes effective April 1, 2026. Eiji Sato will be appointed Director.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7826,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-23931","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n